Base de dados : MEDLINE
Pesquisa : D04.210.500.668.651.693.362 [Categoria DeCS]
Referências encontradas : 61 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 7 ir para página                  

  1 / 61 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22669687
[Au] Autor:Asadi E; Azodi-Deilami S; Abdouss M; Khaghani S
[Ad] Endereço:Department of Chemistry, Amirkabir University of Technology, Tehran, Iran.
[Ti] Título:Cyproterone synthesis, recognition and controlled release by molecularly imprinted nanoparticle.
[So] Source:Appl Biochem Biotechnol;167(7):2076-87, 2012 Aug.
[Is] ISSN:1559-0291
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In this study, we used novel synthetic conditions of precipitation polymerization to obtain nanosized cyproterone molecularly imprinted polymers for application in the design of new drug delivery systems. The scanning electron microscopy images and Brunauer-Emmett-Teller analysis showed that molecularly imprinted polymer (MIP) prepared by acetonitrile exhibited particles at the nanoscale with a high degree of monodispersity, specific surface area of 246 m(2) g(-1), and pore volume of 1.24 cm(3) g(-1). In addition, drug release, binding properties, and dynamic light scattering of molecularly imprinted polymers were studied. Selectivity of MIPs was evaluated by comparing several substances with similar molecular structures to that of cyproterone. Controlled release of cyproterone from nanoparticles was investigated through in vitro dissolution tests and by measuring the absorbance by HPLC-UV. The pH dissolution media employed in controlled release studies were 1.0 at 37 °C for 5 h and then at pH 6.8 using the pH change method. Results show that MIPs have a better ability to control the cyproterone release in a physiological medium compared to the non molecularly imprinted polymers (NMIPs).
[Mh] Termos MeSH primário: Ciproterona/síntese química
Impressão Molecular/métodos
Nanopartículas/química
[Mh] Termos MeSH secundário: Betametasona/química
Ciproterona/química
Preparações de Ação Retardada
Caproato de Gestonorona/química
Concentração de Íons de Hidrogênio
Luz
Nanopartículas/ultraestrutura
Tamanho da Partícula
Polímeros/síntese química
Polímeros/química
Porosidade
Espalhamento de Radiação
Soluções
Solventes
Espectrofotometria Infravermelho
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Delayed-Action Preparations); 0 (Polymers); 0 (Solutions); 0 (Solvents); 9842X06Q6M (Betamethasone); E61Q31EK2F (Cyproterone); U38E620NS6 (Gestonorone Caproate)
[Em] Mês de entrada:1211
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120607
[St] Status:MEDLINE
[do] DOI:10.1007/s12010-012-9748-y


  2 / 61 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:19301570
[Au] Autor:O'Brien JM; Lewis DF
[Ad] Endereço:Perinatal Diagnostic Center, Central Baptist Hospital, Lexington, Kentucky 40503, USA. jobrien@bhsi.com
[Ti] Título:Progestins for the prevention of spontaneous preterm birth: review and implications of recent studies.
[So] Source:J Reprod Med;54(2):73-87, 2009 Feb.
[Is] ISSN:0024-7758
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Progesterone plays a central role in the mechanisms of parturition in many species. Despite remarkable advances in our understanding of this hormone's mechanism of action, its roles in human pregnancy maintenance and parturition are not fully appreciated. Proper scientific hypothesis testing of progestins to prevent preterm birth has been limited because of the issues that can plague interventional trials in obstetrics, including patient selection, choice of outcome and power. The largest studies enrolling patients with a history of prior preterm birth alone to prevent recurrence appear contradictory. In contrast, consistent evidence from one multinational trial and a secondary analysis of another suggests cervical length may serve to identify potential responders to this therapy. Finally, the safety of progestin administration is a legitimate concern and a meta-analysis justifies the need for further investigation of safety issues. This review presents recent findings regarding progestin therapy from both clinical and laboratory data and considers unresolved issues for use of these agents.
[Mh] Termos MeSH primário: Nascimento Prematuro/prevenção & controle
Progestinas/administração & dosagem
[Mh] Termos MeSH secundário: Relação Dose-Resposta a Droga
Feminino
Caproato de Gestonorona/uso terapêutico
Seres Humanos
Estimativa de Kaplan-Meier
Gravidez
Progesterona/fisiologia
Progesterona/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Progestins); 4G7DS2Q64Y (Progesterone); U38E620NS6 (Gestonorone Caproate)
[Em] Mês de entrada:0905
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:090324
[St] Status:MEDLINE


  3 / 61 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:19301566
[Au] Autor:Rittenberg C; Newman RB; Istwan NB; Rhea DJ; Stanziano GJ
[Ad] Endereço:Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC 29425, USA.
[Ti] Título:Preterm birth prevention by 17 alpha-hydroxyprogesterone caproate vs. daily nursing surveillance.
[So] Source:J Reprod Med;54(2):47-52, 2009 Feb.
[Is] ISSN:0024-7758
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To compare the incidence of spontaneous recurrent preterm delivery (SPTD) between women receiving 17 alpha-hydroxyprogesterone caproate (17P) and women receiving daily perinatal nursing surveillance (dPNS) with home uterine activity monitoring. STUDY DESIGN: Women enrolled for dPNS or weekly nursing visits with 17P injection were eligible. Included were singletons with previous SPTD, without preterm labor (PTL), cerclage or vaginal bleeding and < 27 weeks at enrollment. 17P and dPNS patients were matched 1:1 by race, marital status, tobacco use and number of SPTDs. Primary study outcome was incidence of spontaneous PTD. RESULTS: Data from 342 matched pairs were compared. Diagnosis of PTL (39.2% vs. 60.8%) and tocolytic use (12.9% vs. 49.7%) was decreased with 17P vs. dPNS (p < 0.001). The incidences of spontaneous PTD at < 32, 35 and 37 weeks were similar between the groups. CONCLUSION: There was no difference in recurrent SPTD between women treated with 17P and those receiving dPNS.
[Mh] Termos MeSH primário: Caproato de Gestonorona/administração & dosagem
Monitorização Ambulatorial
Trabalho de Parto Prematuro/diagnóstico
Trabalho de Parto Prematuro/prevenção & controle
Progestinas/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Feminino
Serviços de Assistência Domiciliar
Seres Humanos
Injeções Intramusculares
Trabalho de Parto Prematuro/enfermagem
Gravidez
Nascimento Prematuro/prevenção & controle
Estudos Retrospectivos
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Progestins); U38E620NS6 (Gestonorone Caproate)
[Em] Mês de entrada:0905
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:090324
[St] Status:MEDLINE


  4 / 61 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9755895
[Au] Autor:Lipp R; Laurent H; Günther C; Riedl J; Esperling P; Täuber U
[Ad] Endereço:Research Laboratories of Schering AG, Berlin, Germany. ralph.lipp@schering.de
[Ti] Título:Prodrugs of gestodene for matrix-type transdermal drug delivery systems.
[So] Source:Pharm Res;15(9):1419-24, 1998 Sep.
[Is] ISSN:0724-8741
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The aim of this study was to enhance the transdermal absorption of the highly active progestin gestodene from matrix type transdermal delivery systems (TDDS) by formation of prodrugs with improved matrix solubility. METHODS: Gestodene esters were synthesized via acylation of the drug with the respective carboxylic anhydrides. Subsequently TDDS were produced using the solvent cast method. Selected formulations were examined with in vitro diffusion experiments using skin of nude mice. RESULTS: One prodrug, gestodene caproate proved to be an oil at ambient temperature and showed a very high solubilty of over 10.5% in the TDDS matrix. Within in vitro penetration studies using those systems the prodrug exhibited a significantly higher transdermal penetration rate than gestodene from reference systems. Furthermore, the prodrug was hydrolyzed to the parent drug to a high extent during the passage of the skin. CONCLUSIONS: Designing prodrugs to the requirements of matrix TDDS is an efficient way of enhancing the transdermal drug flux rate.
[Mh] Termos MeSH primário: Norpregnenos/administração & dosagem
Pró-Fármacos/administração & dosagem
[Mh] Termos MeSH secundário: Acilação
Administração Cutânea
Animais
Transporte Biológico
Anticoncepcionais Orais Sintéticos/administração & dosagem
Cristalização
Sistemas de Liberação de Medicamentos
Desenho de Drogas
Armazenamento de Medicamentos
Caproato de Gestonorona/administração & dosagem
Caproato de Gestonorona/química
Masculino
Camundongos
Camundongos Nus
Norpregnenos/síntese química
Norpregnenos/química
Pró-Fármacos/química
Congêneres da Progesterona/administração & dosagem
Solubilidade
Temperatura Ambiente
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contraceptives, Oral, Synthetic); 0 (Norpregnenes); 0 (Prodrugs); 0 (Progesterone Congeners); 1664P6E6MI (Gestodene); U38E620NS6 (Gestonorone Caproate)
[Em] Mês de entrada:9812
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:981002
[St] Status:MEDLINE


  5 / 61 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:7513937
[Au] Autor:Iguchi H; Ikeuchi T; Kai Y; Yoshida H
[Ad] Endereço:Department of Urology, Showa University, Fujigaoka Hospital.
[Ti] Título:[Influence of anti-androgen therapy for prostatic hypertrophy on lipid metabolism].
[So] Source:Hinyokika Kiyo;40(3):215-9, 1994 Mar.
[Is] ISSN:0018-1994
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:Antiandrogen therapy has an important role in the treatment of patients with benign prostatic hypertrophy who lack indication for surgery. Herein, the effects on lipid metabolism of administration of antiandrogen agents for benign prostatic hypertrophy are reported. Eighty patients with benign prostatic hypertrophy were each treated with the antiandrogen agents, chlormadinone acetate, allylestrenol, gestonolone caproate and oxendolone for 12 months. The levels of total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), alpha-lipoprotein, apoprotein, and maronediardehyde (MDA) were measured every 4 weeks after initiation of antiandrogen treatment. In the chlormadinone acetate group, the TG level was significantly decreased between 3 and 6 months after treatment (p < 0.05). In the oxendolone group, the alpha-lipoprotein level was also elevated between 3 and 6 months and between 6 to 12 months after treatment (p < 0.05). The MDA level was also significantly elevated 6 and 12 months after treatment. However, the levels of the other lipids were within the normal range. In conclusion, the changes in the levels of plasma lipoprotein, apoprotein and MDA resulting from antiandrogen therapy were unlikely to be a cause of ischemic coronary disease.
[Mh] Termos MeSH primário: Antagonistas de Androgênios/uso terapêutico
Metabolismo dos Lipídeos
Hiperplasia Prostática/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Alilestrenol/uso terapêutico
Acetato de Clormadinona/uso terapêutico
Caproato de Gestonorona/uso terapêutico
Seres Humanos
Lipídeos/sangue
Lipoproteínas HDL/sangue
Masculino
Malondialdeído/sangue
Meia-Idade
Nandrolona/análogos & derivados
Nandrolona/uso terapêutico
Hiperplasia Prostática/sangue
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androgen Antagonists); 0 (Lipids); 0 (Lipoproteins, HDL); 0SY050L61N (Chlormadinone Acetate); 4Y8F71G49Q (Malondialdehyde); 6PG9VR430D (Nandrolone); I47VB5DZ8O (Allylestrenol); MN4I850D4P (oxendolone); U38E620NS6 (Gestonorone Caproate)
[Em] Mês de entrada:9406
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:940301
[St] Status:MEDLINE


  6 / 61 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:7511260
[Au] Autor:Altwein JE; Almer F
[Ti] Título:Is there a change in the treatment of benign prostatic hyperplasia?
[So] Source:Urol Int;52(1):1-3, 1994.
[Is] ISSN:0042-1138
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Mh] Termos MeSH primário: Hiperplasia Prostática/terapia
[Mh] Termos MeSH secundário: Inibidores de 5-alfa Redutase
Idoso
Cateterismo
Caproato de Gestonorona/uso terapêutico
Seres Humanos
Terapia a Laser
Masculino
Prostatectomia
Hiperplasia Prostática/epidemiologia
Terapia por Ultrassom
[Pt] Tipo de publicação:EDITORIAL
[Nm] Nome de substância:
0 (5-alpha Reductase Inhibitors); U38E620NS6 (Gestonorone Caproate)
[Em] Mês de entrada:9404
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:940101
[St] Status:MEDLINE


  7 / 61 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:7516378
[Au] Autor:Di Silverio F; D'Eramo G; Flammia GP; Buscarini M; Frascaro E; Mariani M; Sciarra A
[Ad] Endereço:Department of Urology, U. Bracci, University La Sapienza of Rome, V. Le Policlinico, Italy.
[Ti] Título:[Pharmacological combinations in the treatment of benign prostatic hypertrophy].
[Ti] Título:Associations pharmacologiques dans le traitement de l'hypertrophie prostatique bénigne..
[So] Source:J Urol (Paris);99(6):316-20, 1993.
[Is] ISSN:0248-0018
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:In the development of the obstructive symptomatology of benign prostatic hypertrophy (BPH), two components may be identified, mechanical and dynamic. In the mechanical component, the interaction of a stromal and a epithelial compartment determines prostatic mass growth. The dynamic component involves smooth muscle tone in the prostate and urethra. The consideration that prostatic disease is not only epithelial in origin, but also stromal, leads to the association of an antiandrogen (which acts on the epithelial component) and an antiestrogen (active on the stromal component) in the medical therapy of BPH. In 1985 we carried out a randomized study on 256 BPH patients treated with Cyproterone acetate (CPA) plus Tamoxifen (TAM). Recently, we performed a multicenter double blind study on BPH patients treated with the association CPA plus Serenoa Repens. A statistically significant difference in prostate volume reduction between the groups treated with the combinations and those with the monotherapies was observed. The development of new compounds, such as 5 alpha reductase and aromatase inhibitors, consents to introduce a combination therapy with less side effects. A second pharmacological association may be obtained with drugs acting on the mechanical and others acting on the dynamic (alpha blockers) component of BPH. This combination may associate the early symptomatic effect of alpha blockers with the long term results of a 5 alpha reductase inhibitor, antiestrogen or aromatase inhibitor.
[Mh] Termos MeSH primário: Bromocriptina/uso terapêutico
Acetato de Ciproterona/uso terapêutico
Caproato de Gestonorona/uso terapêutico
Hiperplasia Prostática/tratamento farmacológico
Tamoxifeno/uso terapêutico
[Mh] Termos MeSH secundário: Quimioterapia Combinada
Seres Humanos
Masculino
Extratos Vegetais/uso terapêutico
[Pt] Tipo de publicação:CLINICAL TRIAL; ENGLISH ABSTRACT; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; REVIEW
[Nm] Nome de substância:
0 (Plant Extracts); 094ZI81Y45 (Tamoxifen); 3A64E3G5ZO (Bromocriptine); 4KM2BN5JHF (Cyproterone Acetate); U38E620NS6 (Gestonorone Caproate)
[Em] Mês de entrada:9407
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:930101
[St] Status:MEDLINE


  8 / 61 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:1722627
[Au] Autor:Kanimoto Y; Okada K
[Ad] Endereço:Department of Urology, Fukui Medical School.
[Ti] Título:[Antiandrogen therapy of benign prostatic hyperplasia--review of the agents evaluation of the clinical results].
[So] Source:Hinyokika Kiyo;37(11):1423-8, 1991 Nov.
[Is] ISSN:0018-1994
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:Various non-surgical therapeutic modalities such as balloon dilation of the prostatic urethra, hyperthermia of the prostate and medication with antiandrogens and/or adrenergic blockade have been attempted for the patients with benign prostatic hyperplasia (BPH) especially in an early stage or in a poor operative risk. The observation that androgen deprivation induces shrinkage of the hyperplastic prostate represents the basis for the treatment of BPH with antiandrogen. Although several antiandrogens are now in clinical use in our country, there still remain problems to be solved. We reviewed the mechanism of action and the clinical results of antiandrogens in the treatment of BPH. The improvement following antiandrogen therapy occurred among the patients with symptomatic BPH, in 50-80% subjectively and in 40-50% objectively. The therapy appeared to be more effective in an early stage of the disease. However, the limitation of the duration of the effects and unfavorable side effects should also be noticed. The progestational agents such as gestonorone caproate, chlormadinone acetate and allylestrenol suppress more or less sexual function by interference of the pituitary-gonadal axis. Besides, coincidental prostate cancer must be excluded since antiandrogen therapy might hinder the natural course of the cancer.
[Mh] Termos MeSH primário: Antagonistas de Androgênios/uso terapêutico
Hiperplasia Prostática/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Oral
Alilestrenol/uso terapêutico
Acetato de Clormadinona/uso terapêutico
Esquema de Medicação
Avaliação de Medicamentos
Caproato de Gestonorona/uso terapêutico
Seres Humanos
Masculino
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androgen Antagonists); 0SY050L61N (Chlormadinone Acetate); I47VB5DZ8O (Allylestrenol); U38E620NS6 (Gestonorone Caproate)
[Em] Mês de entrada:9202
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:911101
[St] Status:MEDLINE


  9 / 61 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:3330126
[Au] Autor:Adler A; Gillon G; Lurie H; Shaham J; Loven D; Shachter Y; Shani A; Servadio C; Stein JA
[Ad] Endereço:Institute of Oncology, Beilinson Medical Center, Petah-Tiqva, Israel.
[Ti] Título:Active specific immunotherapy of renal cell carcinoma patients: a prospective randomized study of hormono-immuno-versus hormonotherapy. Preliminary report of immunological and clinical aspects.
[So] Source:J Biol Response Mod;6(6):610-24, 1987 Dec.
[Is] ISSN:0732-6580
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Early results of a prospective, randomized trial of active, specific immunotherapy adjunctive to nephrectomy in all stages of RCC are presented. Forty-three patients with median followup of 30 m, who were randomly allocated to either immuno-hormonotherapy arm (IMT), or hormonotherapy alone (HT), are evaluated in terms of progression-free interval (PFI) and overall survival by life table method. Immunotherapy consisted of autologous irradiated tumor cells (AITC), admixed with bacillus Calmette-Guérin (Glaxo) administered by the intradermal and endolymphatic route. Clinical results of this study show only a trend for advantage of the experimental (IMT) arm over the control (HT) arm, this trend did not reach statistical significance level: prolongation of disease free period in stages I-III with localized disease (p less than 0.1) and prolongation of survival in patients with metastatic disease (p less than 0.07). A correlation was established between induction of cutaneous delayed hypersensitivity (DTH) to AITC and prolonged PFI and survival: patients with positive DTH had a significantly better course of disease than those who could not be converted to positivity after repeated immunizations. Positive in vitro leukocyte migration inhibition against autologous tumor preparations correlates well with positive in vivo cutaneous DTH. Some immunological aspects of active immunization with autologous tumor cells are discussed.
[Mh] Termos MeSH primário: Carcinoma de Células Renais/terapia
Imunoterapia
Neoplasias Renais/terapia
[Mh] Termos MeSH secundário: Vacina BCG/uso terapêutico
Carcinoma de Células Renais/tratamento farmacológico
Carcinoma de Células Renais/imunologia
Inibição de Migração Celular
Ensaios Clínicos como Assunto
Terapia Combinada
Feminino
Caproato de Gestonorona/uso terapêutico
Seres Humanos
Hipersensibilidade Tardia
Neoplasias Renais/tratamento farmacológico
Neoplasias Renais/imunologia
Leucócitos/imunologia
Masculino
Estudos Prospectivos
Distribuição Aleatória
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (BCG Vaccine); U38E620NS6 (Gestonorone Caproate)
[Em] Mês de entrada:8807
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:871201
[St] Status:MEDLINE


  10 / 61 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:3743604
[Au] Autor:Runge HM; Neumann HA; Bauknecht T; Pfleiderer A
[Ti] Título:Growth patterns and hormonal sensitivity of primary tumor, abdominal metastasis and ascitic fluid from human epithelial ovarian carcinomas in the tumor colony-forming assay.
[So] Source:Eur J Cancer Clin Oncol;22(6):691-6, 1986 Jun.
[Is] ISSN:0277-5379
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The human tumor colony forming assay was used to evaluate the response of ovarian carcinoma cells from primary tumors, ascitic fluids and metastasis to hormonal treatment. In 12/35 patients a sufficient colony formation (greater than 30 colonies/dish) was obtained in order to perform a simultaneous drug testing. The plating efficiency of the metastatic samples (0.12%) was significantly higher (P less than 0.053) than those from the primary tumor (0.076%) or those that were derived from the ascitic fluid (0.082%). Colonies from the metastatic tissues could be evaluated 2-4 days earlier than those from primary tumors. These discrepancies may be due to a heterogeneity in the clonable tumor cell compartment of primary tumor and metastasis. The antiproliferative properties of the antiestrogen tamoxifen and the progestin gestoneron were studied. In 9/12 cases a significant, dose-dependent reduction of colony formation (greater than 70-90% of the controls) was observed after continuous exposure to 1 mumole tamoxifen. No correlation between the dose response and the content of steroid receptors was found. Even estrogen receptor negative tumor samples showed a maximal antiproliferative effect of tamoxifen.
[Mh] Termos MeSH primário: Neoplasias Abdominais/secundário
Líquido Ascítico/patologia
Neoplasias Ovarianas/patologia
[Mh] Termos MeSH secundário: Neoplasias Abdominais/patologia
Células Clonais/efeitos dos fármacos
Ensaio de Unidades Formadoras de Colônias
Relação Dose-Resposta a Droga
Feminino
Caproato de Gestonorona/farmacologia
Seres Humanos
Mitose/efeitos dos fármacos
Receptores Estrogênicos/análise
Receptores de Progesterona/análise
Tamoxifeno/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Receptors, Estrogen); 0 (Receptors, Progesterone); 094ZI81Y45 (Tamoxifen); U38E620NS6 (Gestonorone Caproate)
[Em] Mês de entrada:8610
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:860601
[St] Status:MEDLINE



página 1 de 7 ir para página                  
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde